Quantcast

Latest Biosimilar Stories

2014-08-20 23:09:43

The human insulin market is segmented based on types of insulin, and branded drugs available in the market (http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html). (PRWEB) August 20, 2014 The “Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019” provides a...

2014-08-20 23:08:43

The August issue of Atlantic Information Services’s Specialty Pharmacy News offers coverage of recent developments in the biosimilars specialty pharmacy segment, including the Food and Drug Administration’s recent acceptance of a biosimilar application, the first step towards approval. Washington, DC (PRWEB) August 20, 2014 Biosimilars, which are similar versions of branded biologic drugs that are approved through an abbreviated process, could reap billions in health care savings. The...

2014-08-18 12:27:41

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "The Overveiw of Japanese Generic Drug Market" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report talks about the overview of Japanese generic drug market. It gives the readers ann understanding of the overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend,...

2014-08-14 16:27:44

Company To Pursue Next Stage of Development REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(®) in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined,...

2014-08-11 12:28:18

Twenty-five pharmaceutical companies being asked to adopt common principles re biosimilars on patient safety, lobbying and business partnerships. DETROIT, Aug. 11, 2014 /PRNewswire/ -- A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor...

2014-07-30 12:30:51

Step Edits Are the Most Likely Strategy to Drive Use of a Biosimilar Priced 30 Percent Less than the Reference Brand, According to Findings from Decision Resources Group BURLINGTON, Mass., July 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the majority of surveyed pharmacy and medical directors in the United States believe that the key drivers of biosimilar market penetration will be the level of savings achievable by their managed care organizations (MCOs) and the expected...

2014-07-29 23:07:36

MarketOptimizer.org adds “PharmaSphere Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market” to its store. The report discusses the various regulatory frameworks under which biosimilars are currently reviewed and regulated. Dallas, Texas (PRWEB) July 29, 2014 PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. Using detailed...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-07-23 23:23:16

The human insulin market is segmented based on types of insulin, and branded drugs available in the market. http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html. (PRWEB) July 22, 2014 The “Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019” provides a...

2014-07-23 23:16:58

New research report “Botulinum Neurotoxins: A Comparative Industry Analysis Of Products, Pipelines, Technologies And Stakeholders” prepared by La Merie Publishing is now available at MarketPublishers.com. London, UK (PRWEB) July 22, 2014 The market for botulinum neurotoxin (BoNT) products has grown considerably over the past few years, owing to novel medical indications created and due to more cosmetic procedures performed with BoNTs in the aging societies where physical appearance is...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.